TIANJIN, CHINA, January 2, 2020, CanSino Biologics Inc. (“CanSinoBIO” or the “Company”, 6185.HK) announced the appointment of Dr. Pierre Armand Morgon as Senior Vice President responsible for international business operation. The appointment indicated a further step forward in the Company’s commitment to global development and growth.

Dr. Morgon will report to Chairman and Chief Executive Officer Dr. Xuefeng Yu and will lead the Company’s overall branding and product growth strategies, industry collaboration and partnership programs in international markets other than China.

“I’m delighted to welcome Dr. Morgon to join us as a member of the management team. He has impressive achievements in pharmaceutical marketing and management. I believe his experience, expertise and vision will play an important role in expanding international markets and promoting the development of the Company.” said Dr. Xuefeng, Yu, the Chairman and CEO of CanSinoBIO. 

Dr. Morgon has over 30 years of experience in leading pharmaceutical organizations with expertise in global marketing, strategies and management. He was Senior Vice President at Sanofi Pasteur responsible for franchising and global marketing, and Vice President and Director of Hospital Operations at Bristol-Myers Squibb. Additionally, he held senior management positions responsible for marketing and operations respectively at Imperial Chemical Industries Pharma, Synthelabo, Aventis Pasteur, Yamanouchi Pharma Co. and Schering-Plough Corporation, etc.

Dr. Morgon received his master’s degree in marketing management from ESSEC Business School in October 1988 and a diploma of advanced studies in commercial law and economic law from Jean Moulin University Lyon 3, France in November 1986. He received his doctorate degree in pharmacy from Claude Bernard University Lyon 1, France in July 1985.

In addition, Dr. Morgon has been recognized as one of the Top 50 vaccine influencers in 2013.

About CanSino Biologics Inc.

Incorporated in 2009, CanSinoBIO (6185.HK) commits to research, development, production and commercialization of innovative vaccines for China and global public health. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 15 candidate vaccines covering 12 diseases, including a globally innovative Ebola virus disease vaccine approved for emergency use and stockpile in 2017.